Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure.
about
Role of Gas6 in erythropoiesis and anemia in miceA Population Pharmacokinetic and Pharmacodynamic Analysis of Peginesatide in Patients with Chronic Kidney Disease on DialysisSwitching patients with non-dialysis chronic kidney disease from oral iron to intravenous ferric carboxymaltose: effects on erythropoiesis-stimulating agent requirements, costs, hemoglobin and iron statusHepcidin-25 in chronic hemodialysis patients is related to residual kidney function and not to treatment with erythropoiesis stimulating agentsThe impact of renal insufficiency and anaemia on survival in patients with cardiovascular disease: a cohort studyEffect of rosuvastatin on outcomes in chronic haemodialysis patients: baseline data from the AURORA study.Would artificial neural networks implemented in clinical wards help nephrologists in predicting epoetin responsiveness?Optimal and continuous anaemia control in a cohort of dialysis patients in SwitzerlandAnaemia management with subcutaneous epoetin delta in patients with chronic kidney disease (predialysis, haemodialysis, peritoneal dialysis): results of an open-label, 1-year study.The importance of iron in long-term survival of maintenance hemodialysis patients treated with epoetin-alfa and intravenous iron: analysis of 9.5 years of prospectively collected dataHFE mutations modulate the effect of iron on serum hepcidin-25 in chronic hemodialysis patients.Maintaining over time clinical performance targets on anaemia correction in unselected population on chronic dialysis at 20 Italian centres. Data from a retrospective study for a clinical audit.Comparison of the renal, cardiovascular and hepatic toxicity data of original intravenous iron compounds.Iron and infection in hemodialysis patientsThe Resection of Thyroid Cancer Was Associated with the Resolution of Hyporesponsiveness to an Erythropoiesis-stimulating Agent in a Hemodialysis Patient with AceruloplasminemiaExtended dosing of darbepoetin alfa in peritoneal dialysis patients.The effects of probiotic supplement on hemoglobin in chronic renal failure patients under hemodialysis: A randomized clinical trial.The safety and efficacy of intravenous ferric carboxymaltose in anaemic patients undergoing haemodialysis: a multi-centre, open-label, clinical study.Improvements in renal replacement therapy practice patterns in estoniaBaseline characteristics of patients with chronic kidney disease stage 3 and stage 4 in Spain: the MERENA observational cohort studySafety and Efficacy of PDpoetin for Management of Anemia in Patients with end Stage Renal Disease on Maintenance Hemodialysis: Results from a Phase IV Clinical Trial.Endotoxaemia in haemodialysis: a novel factor in erythropoetin resistance?Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trialHemoglobin variability does not predict mortality in European hemodialysis patients.Stable hemoglobin in hemodialysis patients: forest for the trees--a 12-week pilot observational studyThe development of anemia is associated to poor prognosis in NKF/KDOQI stage 3 chronic kidney diseasePredialysis therapeutic care and health-related quality of life at dialysis onset (The pharmacoepidemiologic AVENIR study).The A736V TMPRSS6 polymorphism influences hepcidin and iron metabolism in chronic hemodialysis patients: TMPRSS6 and hepcidin in hemodialysis.Predicting erythropoietin resistance in hemodialysis patients with type 2 diabetesUnexpected Hypotensive Events during Preparatory Plasmaphereses.Effect of occasional epoetin use in combination with a stable darbepoetin dosage on anemia management in hemodialysis patients.Erythrocyte and Reticulocyte Indices on the LH 750 as Potential Markers of Functional Iron Deficiency.Erythropoiesis-stimulating agent resistance and mortality in hemodialysis and peritoneal dialysis patients.Resistance to erythropoiesis stimulating agents in patients treated with online hemodiafiltration and ultrapure low-flux hemodialysis: results from a randomized controlled trial (CONTRAST)Population pharmacokinetic meta-analysis to bridge ferumoxytol plasma pharmacokinetics across populations.Do two intravenous iron sucrose preparations have the same efficacy?Iron therapy for renal anemia: how much needed, how much harmful?Resistance of dialyzed patients to erythropoietin.Characterization of chronic and acute ESA hyporesponse: a retrospective cohort study of hemodialysis patients.[Predictors of response to the CERA in chronic hemodialysis treatment-naive by erythropoiesis-stimulating agent].
P2860
Q28513935-77F0E6A7-C880-43E4-9584-AF8B3F09AA6EQ28533979-FE5943F6-1B12-4060-B424-75166E964FC9Q28648176-C43A2B52-5820-4149-875E-6FACBEFB37DCQ28727076-BF982E98-6960-4FF6-BC79-C970160F51C2Q30883735-4E96956D-888C-42C8-993D-278049BD9AE9Q31120569-551F4BC7-C56F-48EF-908E-1C2DFB3F0E77Q33257895-D86BC733-44AF-4587-AE48-162542393D5BQ33392426-1ECB4D40-8904-49D3-B714-D123FFD0F82CQ33412594-D09ECD29-B2F4-414D-90FC-14EB7235996FQ33412890-9F85AA4E-FB16-4C2B-B065-7F5954F490D0Q33471093-4FCE4308-E417-419B-B6A5-59852F2C0625Q33512133-439C13FF-425D-402A-8215-FFBC7980F9F3Q33583025-BB0F1477-5917-4483-8088-753055D8AABBQ33591327-1E95CFA1-3154-4F99-82D8-0012B3934505Q33760759-6E079371-4F89-450B-A37B-A1E968C01FA7Q33854988-5740930B-E2AC-449E-8008-58C1D64E66CDQ33900683-4FFDD9B9-225B-4534-835F-E77A1FEB9C66Q34000965-AFED99FA-B548-4586-87B5-A4393C922A12Q34036570-B646D5F7-13EB-4851-8D6F-EEF30459CC6DQ34039724-6DBFF206-311D-4DCC-B91F-7447500FAE3DQ34325810-84189DCD-6F7E-490C-97D5-380458C9C343Q34328779-59766FDC-D6D2-4C7F-AF01-18421A3F1D3CQ34340711-63471720-1F51-4C35-94DA-29FE028B2464Q34455408-56E2980F-6038-41CE-A2A8-074806022147Q34493460-D77068A2-48EF-4857-92F7-06B5EE8CDDAEQ34538362-2BC1BEB2-023A-4ED3-8DDB-6362209A52CBQ34564232-45025906-419D-4D91-8BF5-A6B5C71751A8Q34596298-E7955B74-EE54-4F94-8377-833E80CCC5E7Q34632482-DCF93559-0825-4B3C-9F60-72533531A0B2Q34687316-8095B7A3-DC44-4EA7-A309-4F2D2AD76E07Q34700889-F2D49A1F-43C5-43E0-898C-F0F568731B16Q34730125-3C2178D3-3D7A-460D-93E8-BF34FBE31B7FQ34997753-07963C58-E870-4DC4-B72B-E8482C2E03CCQ35151878-829CB260-6E6D-4521-A7CE-8443DCC9DBF1Q35203534-5C43A3DD-ADED-4503-9757-D47EA4014B38Q35344826-EDBA4403-9E0D-4032-9B2E-FB552D61BDABQ35650627-128C3C32-77CF-4210-8D1D-B2E0F63F4036Q35694046-E65CF9C2-D45E-499E-A41C-C5CB73C7E0BBQ35748297-9008BEDD-D964-4FDB-ADFE-285EBA789927Q35817602-19F1DE33-5D77-400C-BBEC-FBB1A7F09349
P2860
Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Revised European best practice ...... ts with chronic renal failure.
@ast
Revised European best practice ...... ts with chronic renal failure.
@en
type
label
Revised European best practice ...... ts with chronic renal failure.
@ast
Revised European best practice ...... ts with chronic renal failure.
@en
prefLabel
Revised European best practice ...... ts with chronic renal failure.
@ast
Revised European best practice ...... ts with chronic renal failure.
@en
P2093
P356
P1476
Revised European best practice ...... ts with chronic renal failure.
@en
P2093
Alison Macleod
Andrzej Wiecek
Bernard Canaud
European Best Practice Guidelines Working Group
Fernando Carrera
Francesco Locatelli
Iain C Macdougal
Kai-Uwe Eckardt
Pedro Aljama
Peter Bárány
P304
P356
10.1093/NDT/GFH1032
P407
P478
19 Suppl 2
P577
2004-05-01T00:00:00Z